

**DINSMORE
& SHOHL LLP****FACSIMILE TRANSMITTAL**

October 4, 2001

from **HOLLY D. KOZLOWSKI**

Direct: 513-977-8568 / Fax: 513-977-8141 / kozlowsk@dinslaw.com

To: Art Unit 1615
Examiner A. Pulliam
Firm: U.S. Patent & Trademark Office (USPTO)
Fax Number: 703/305-3592
Client Number: 10914-11
Pages: 12
(including cover)

FAX RECEIVED
OCT 05 2001
GROUP 1600

Comments:

TH 16: 35

If there are any problems in receiving this transmission, please call the fax room at (513) 977-8483 immediately. Thank you.

Notice

This message is intended only for the use of the individuals or entity to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure under applicable law. If the reader of this notice is not the intended recipient or the employee or agent responsible for delivering this message to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this notice in error, please notify us immediately by telephone and return these papers to us at the address below via first class mail.


Cincinnati • 1900 Chemed Center • 255 East Fifth Street • Cincinnati, OH 45202 • Phone: (513) 977-8200

Docket No. 10914-11

PATENT

CERTIFICATE OF FACSIMILE

I hereby certify that this paper is being transmitted via facsimile to Group Art Unit 1615; Box AF; Assistant Commissioner of Patents, Washington, DC 20231 at facsimile number 703/305-3592 on October 4, 2001.

13/C **IN THE UNITED STATES PATENT & TRADEMARK OFFICE**

Applicant: Isa Odidi et al : Paper No.:
Serial No. : 09/403,437 : Group Art Unit: 1615
Filed: October 21, 1999 : Examiner: A. Pulliam
For: **Controlled Release Formulations Using Intelligent Polymers**

Ret
10-15-01**AMENDMENT UNDER 37 CFR 1.116**


Box AF
Assistant Commissioner for Patents
Washington, DC 20231

Dear Sir:

In response to the Office Action dated May 4, 2001 in the above-referenced application, please amend the application as follows:

In the Claims

Please amend claims 1 and 30 to read as follows:

- 
1. (Twice Amended) A controlled release pharmaceutical composition comprising:
- (a) at least one pharmaceutically active substance having a water contact angle (θ) such that $\cos \theta$ is between +0.9848 and -0.9848;
 - (b) a first intelligent polymer component; and
 - (c) a second intelligent polymer component having opposite wettability characteristics to said first intelligent polymer component, said second intelligent polymer component comprising hydroxyethylcellulose or a mixture of hydroxyethylcellulose and hydroxypropyl methyl cellulose, the first and second polymer components being present in a ratio in the range of about 1:100 to about 100:1 by weight,